EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Testosterone therapy in older men: clinical implications of recent landmark trials

Mathis Grossmann iD, Bradley D Anawalt, Bu B Yeap

European Journal of Endocrinology · 2024

DOI: 10.1093/ejendo/lvae071 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Mathis Grossmann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria 3084, Australia. Hauptthemen laut MEDLINE: Testosterone, Hypogonadism. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Testosterone therapy for men with hypogonadism due to identifiable hypothalamic-pituitary-testicular (HPT) pathology is uncontroversial. However, the risks and benefits of testosterone for men with clinical features of hypogonadism in the absence of identifiable HPT axis pathology have been uncertain. Recent landmark placebo-controlled trials assessed the benefits and risks of testosterone therapy (≤3 years) for middle-aged and older men with symptoms and possible signs of hypogonadism or end-organ androgen deficiency, low or low-normal serum testosterone concentrations, but no HPT pathology: Testosterone therapy (1) had modest—but clinically significant—benefits on average self-reported energy and mood, sexual function, and satisfaction; (2) in conjunction with a lifestyle programme, reversed or reduced incident type 2 diabetes mellitus (T2D) in men at high risk of or newly diagnosed with T2D; (3) modestly improved objectively assessed muscle strength and timed walking distance; (4) increased bone density and strength, but did not reduce falls or typical osteoporotic fractures and surprisingly increased the risk of fractures typically attributable to trauma; and (5) did not significantly increase the risk of myocardial infarction, stroke, or prostate cancer. These landmark trials help to inform clinical decision-making about testosterone therapy for men.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneHypogonadismHumansMaleAgedHormone Replacement TherapyMiddle AgedDiabetes Mellitus, Type 2Androgens

Stichwörter der Autor:innen

aging menandrogen deficiencyhypogonadismtestosteronetestosterone therapy

Substanzen

TestosteroneAndrogens

Autor:innen und Institutionen

  • Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria 3084, Australia.
  • Department of Endocrinology, Austin Health, Heidelberg, Victoria 3084, Australia.
  • Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, United States.
  • Medical School, University of Western Australia, Perth, Western Australia 6009, Australia.
  • Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia.

ORCID-Profile: Mathis Grossmann

Zitieren

APA

Grossmann, M., Anawalt, B. D., & Yeap, B. B. (2024). Testosterone therapy in older men: clinical implications of recent landmark trials. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae071

Vancouver

Grossmann M, Anawalt BD, Yeap BB. Testosterone therapy in older men: clinical implications of recent landmark trials. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae071

BibTeX
@article{Grossmann2024,
  author = {Grossmann, Mathis and Anawalt, Bradley D and Yeap, Bu B},
  title = {Testosterone therapy in older men: clinical implications of recent landmark trials},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae071}
}
Kostenlos starten →